EXCELYA/XENOTHERA
3.5.2021 12:15:09 CEST | Business Wire | Press release
The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya , a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multi-center, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored remotely. The trial will take place in Greece, Bulgaria, Romania, Spain and Turkey.
The first patient in the trial was recruited on April 28th at Professor Poulakou's center (GR04) in Greece. The cohort of 722 patients will complement the 398 patients in the POLYCOR trial, a trial carried out in 35 French hospitals under the sponsorship of the Nantes University Hospital, which has just closed its recruitment phase with results expected Summer 2021.
"Excelya is very proud to support XENOTHERA in the development of XAV19, which holds great promise in the battle against COVID19. After taking several months to develop the EUROXAV project, the inclusion of this first patient represents an important milestone. We hope to work quickly to make results available and initiate the next steps to benefit patients and caregivers," said Alan Morgan, CEO of Excelya .
“This milestone marks the start of the EUROXAV trial, the results of which are awaited with great interest. The aim of the trial is to evaluate the efficacy of XAV-19 in hospitalized and ambulatory patients, which will allow us to analyze the medical value of XAV-19 in clinical situations where there is currently no satisfactory therapeutic solution.” comments Odile Duvaux, co-founder and president of XENOTHERA.
*********************
About XAV-19:
XENOTHERA's drug candidate XAV-19 is a protective anti-SARS-CoV-2 polyclonal antibody similar to the natural human response
. Based on a unique and patented proprietary technology, it acts through several mechanisms of action, including neutralizing the virus, reducing inflammation and limiting the risk of cytokine storms.
About XENOTHERA:
Founded in 2014, XENOTHERA is a Nantes-based biotech company that develops "glyco-humanized" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the beginning of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by the biotech.
XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire. The company has been supported since its creation by private investors, by the Pays de la Loire Region and by BPI France. Since its creation, the company has raised more than 23 million euros to finance all of its products.
For more information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn
Twitter
About Excelya Group:
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005365/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Santander Financial Crime Transformation Leader Joins ThetaRay to Drive Enterprise AI Adoption7.7.2026 10:00:00 CEST | Press release
As Chief Strategic Customers Officer, former Group VP Luis Pinedo will scale ThetaRay’s AI compliance infrastructure across global banks, payment providers and financial institutions. ThetaRay, a leader in AI infrastructure for financial crime compliance, today announced the appointment of Luis Pinedo as Chief Strategic Customers Officer. Previously Pinedo was Group VP of Compliance at Santander Bank, where during his 16-year tenure, he led global Financial Crime Compliance (FCC) transformation initiatives across operating models, processes, and technology platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707359150/en/ Luis Pinedo joins ThetaRay as Chief Strategic Customers Officer. In his new role, Pinedo will bring key perspectives from tier-one banking operational challenges to ThetaRay’s product development and design. He will lead strategic customer engagement as well as product strategy across ThetaRay’s ent
Robbyant Unveils LingBot-Depth 2.0 and LingBot-Vision to Redefine Robotic Spatial Perception7.7.2026 09:54:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the launch of LingBot-Depth 2.0, a next-generation spatial perception model, alongside its foundational visual model, LingBot-Vision. This release marks a significant leap in robotic spatial perception, empowering robots to accurately understand and navigate the physical world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806935/en/ LingBot-Depth 2.0 reconstructs complete and planar 3D structures in challenging scenarios involving mirrors and glass From "Seeing" to "Seeing Accurately" Building upon the success of LingBot-Depth, which pioneered the Masked Depth Modeling (MDM) technique to resolve depth sensing challenges for transparent and reflective surfaces, LingBot-Depth 2.0 represents a massive scale-up in training data and performance. Trained on 150 million samples, the new model achieves top rankings in 12 out of 16 depth completion benchmarks.
RGI Group Strengthens Its Personal Insurance Capabilities in France Through KAPIA-RGI’s Acquisition of Cegid Assurex Solutions7.7.2026 09:30:00 CEST | Press release
RGI, a leading European provider of digital insurance platforms, announces that KAPIA-RGI, its France-based company specialised in personal insurance solutions, has acquired Cegid Assurex solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707323665/en/ This transaction marks a major milestone in the Group's development strategy in French speaking markets in Europe and further enhances its ability to support insurers, mutual insurers, provident institutions, brokers and bancassurers in their innovation and digital transformation initiatives. By integrating Cegid Assurex's expertise, talent and solutions, KAPIA-RGI consolidates its position as the reference leader in the Life Insurance, Savings, Retirement, Annuities and Provident markets. This acquisition expands its client base with more than 20 additional customers while accelerating innovation and growth in a market shaped by evolving regulation, automation and a
Bitcoin Suisse Advances Middle East Expansion, Receiving Financial Services Permission in Abu Dhabi7.7.2026 09:15:00 CEST | Press release
Premium virtual assets pioneer BTCS (Middle East) Ltd. is now fully authorized by the Financial Services Regulatory Authority (FSRA) of ADGM, enabling regulated institutional services across the UAE. Building on its position as Switzerland’s leading crypto financial services provider, Bitcoin Suisse is further accelerating its international expansion. Bitcoin Suisse Group’s subsidiary, BTCS (Middle East) Ltd. (“BTCS ME”) has received Financial Services Permission (FSP) from the Financial Services Regulatory Authority (FSRA) of ADGM, the international financial centre of Abu Dhabi, marking another significant step toward the Group’s international growth strategy becoming a leading global wealth management partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707864200/en/ Ceyda Majcen, Chief Executive Officer and SEO of BTCS ME, leads Bitcoin Suisse Group's expansion in the Middle East and brings extensive, long-standing
Alpaca Completes EEA Passporting to 29 Countries, Expanding Access to Regulated Investment Services Across Europe7.7.2026 09:00:00 CEST | Press release
Alpaca now provides regulated, localized investment services across the European Economic Area Alpaca, a global leader in brokerage infrastructure APIs, today announced that it has completed the process to passport its regulated and localized investment services across 29 countries in the EEA (European Economic Area) through its Spain-based EEA hub. The completion of EEA passporting enables Alpaca to extend the regulatory foundation established through its European entity, which is authorized and registered with Spain’s Comisión Nacional del Mercado de Valores (CNMV), across the EEA under the MiFID II framework. Together with Alpaca’s regulated UK entity, this milestone strengthens Alpaca’s ability to support fintechs, financial institutions, and enterprise partners building regulated investment products across Europe, reaching a market of nearly 500 million people. The passported countries include Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom